Literature DB >> 9868657

Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease.

N Jabado1, J L Casanova, E Haddad, F Dulieu, J C Fournet, B Dupont, A Fischer, C Hennequin, S Blanche.   

Abstract

Scedosporium apiospermum is an opportunistic fungus in humans. The incidence of S. apiospermum infection in patients with acquired neutropenia (e.g., patients receiving chemotherapy and bone marrow transplant recipients) is steadily increasing. S. apiospermum has poor in vitro susceptibility to "conventional" antifungal agents, rendering the management of infections complex. Patients with chronic granulomatous disease (CGD) are highly susceptible to fungal infections, which are mostly due to Aspergillus species. We describe two children with CGD and invasive pulmonary infection due to S. apiospermum. Both patients were treated with antifungal therapy including azole derivatives (itraconazole or voriconazole) and surgical resection of infected tissues. These cases highlight that scedosporium infection can closely mimic aspergillus infection and should be considered in any case in which there is a failure to respond to appropriate "conventional" antifungal therapy. We also suggest that the emergence of this pathogen may have been favored by long-term use of amphotericin B in both patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9868657     DOI: 10.1086/515015

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  29 in total

Review 1.  A persistent challenge: the diagnosis of respiratory disease in the non-AIDS immunocompromised host.

Authors:  C Mayaud; J Cadranel
Journal:  Thorax       Date:  2000-06       Impact factor: 9.139

Review 2.  Chronic granulomatous disease.

Authors:  D Goldblatt; A J Thrasher
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

3.  Scedosporium apiospermum in chronic granulomatous disease treated with an HLA matched bone marrow transplant.

Authors:  M M Gompels; C A Bethune; G Jackson; G P Spickett
Journal:  J Clin Pathol       Date:  2002-10       Impact factor: 3.411

Review 4.  Mucormycosis, pseudallescheriasis, and other uncommon mold infections.

Authors:  Clifford Quan; Brad Spellberg
Journal:  Proc Am Thorac Soc       Date:  2010-05

Review 5.  Enzymatic Mechanisms Involved in Evasion of Fungi to the Oxidative Stress: Focus on Scedosporium apiospermum.

Authors:  C Staerck; P Vandeputte; A Gastebois; A Calenda; S Giraud; N Papon; J P Bouchara; M J J Fleury
Journal:  Mycopathologia       Date:  2017-06-21       Impact factor: 2.574

6.  In vitro activities of four novel triazoles against Scedosporium spp.

Authors:  A J Carrillo; J Guarro
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

7.  Correlation between in vitro susceptibility of Scedosporium apiospermum to voriconazole and in vivo outcome of scedosporiosis in guinea pigs.

Authors:  Javier Capilla; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 8.  Infections caused by Scedosporium spp.

Authors:  Karoll J Cortez; Emmanuel Roilides; Flavio Quiroz-Telles; Joseph Meletiadis; Charalampos Antachopoulos; Tena Knudsen; Wendy Buchanan; Jeffrey Milanovich; Deanna A Sutton; Annette Fothergill; Michael G Rinaldi; Yvonne R Shea; Theoklis Zaoutis; Shyam Kottilil; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

9.  Pulmonary aspergillosis in a patient with chronic granulomatous disease: confirmation by polymerase chain reaction and serological tests, and successful treatment with voriconazole.

Authors:  H Sambatakou; M Guiver; D Denning
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-10-18       Impact factor: 3.267

10.  Infection with Scedosporium apiospermum and S. prolificans, Australia.

Authors:  Louise Cooley; Denis Spelman; Karin Thursky; Monica Slavin
Journal:  Emerg Infect Dis       Date:  2007-08       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.